Aspira Women's Health Announces The Publication Of Three Abstracts By The American Society Of Clinical Oncology Supporting The Clinical Utility Of OvaSuite Ovarian Cancer Risk Assessment Tests
Portfolio Pulse from Happy Mohamed
Aspira Women's Health (NASDAQ: AWH) announced the publication of three abstracts supporting the clinical utility of OvaWatch, an ovarian cancer risk assessment test, at the 2023 American Society of Clinical Oncology Meeting. The abstracts confirm OvaWatch as an industry-leading test that can safely reduce premature surgeries in the management of adnexal masses.
May 31, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aspira Women's Health's OvaWatch receives support from three abstracts published at the 2023 ASCO Meeting, confirming its clinical utility as an industry-leading ovarian cancer risk assessment test.
The publication of the abstracts supporting the clinical utility of OvaWatch at the 2023 ASCO Meeting is a positive development for Aspira Women's Health. This confirmation of OvaWatch as an industry-leading ovarian cancer risk assessment test can potentially lead to increased adoption and revenues for the company, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100